Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Aura Biosciences, Inc. (NASDAQ: AURA), a Boston-based clinical-stage biotechnology company developing precision therapies for solid tumors that aim to preserve organ function. These regulatory documents provide detailed insight into AURA’s financial condition, clinical development plans, governance, and capital markets activity.
Among the most frequently referenced filings are Aura’s Form 10-K annual reports and Form 10-Q quarterly reports, which describe the company’s business, risk factors, research and development focus on bel-sar (AU-011), and operating expenses tied to its global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, additional ocular oncology programs, and non-muscle invasive bladder cancer. Investors can also review Form 8-K current reports, such as those filed on dates when Aura announces quarterly results or updates its corporate presentation, to see how the company communicates material events and financial updates.
For users interested in ownership and governance, SEC filings provide information on matters submitted to stockholder votes, including director elections and auditor ratification, as illustrated by Aura’s Form 8-K reporting results of its annual meeting of stockholders. Registration statements and prospectus supplements related to public offerings of common stock and warrants detail how the company raises capital to fund its clinical programs and general corporate purposes.
Stock Titan’s platform enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly understand clinical priorities, cash runway disclosures, and risk factor discussions without reading every page. Real-time updates from EDGAR ensure new AURA filings appear promptly, while structured access to forms such as 10-K, 10-Q, 8-K, and registration statements allows investors to navigate Aura Biosciences’ regulatory history efficiently.
Aura Biosciences files its annual report describing a clinical‑stage biotech focused on precision therapies for solid tumors, led by its virus‑like drug conjugate bel-sar.
Bel-sar is in a global Phase 3 trial for early choroidal melanoma and earlier trials showed 80% tumor control and 90% vision preservation in selected patients. The company is also developing bel-sar for metastases to the choroid and non‑muscle invasive bladder cancer, where early Phase 1 data showed local tumor responses and immune activation. Aura reports recurring losses, expects continued losses, and its auditors issued a “going concern” opinion, underscoring heavy dependence on future financings and on bel-sar’s clinical and regulatory success.
Aura Biosciences reported full-year 2025 results and updated its oncology pipeline. The company is advancing bel-sar, a virus-like drug conjugate, across ocular and urologic cancers. Its global Phase 3 CoMpass trial in early choroidal melanoma is enrolling faster than expected, with enrollment now targeted for completion by mid-2026 and topline data expected in the second half of 2027. A Phase 1b/2 trial in non-muscle-invasive bladder cancer is on track, with initial three-month data anticipated mid-2026, and multiple proof-of-concept ocular oncology studies are expected to read out in 2026.
As of December 31, 2025, Aura held $144.2 million in cash, cash equivalents and marketable securities and believes this will fund operations into the first quarter of 2027. Research and development expenses were $90.3 million for 2025, up from $73.3 million in 2024, reflecting progress of the Phase 3 melanoma trial and higher personnel costs. General and administrative expenses were $22.5 million, slightly below 2024 levels.
Net loss for 2025 was $106.2 million compared with $86.9 million in 2024, and basic and diluted net loss per share was $1.76 versus $1.75. Weighted average shares outstanding increased to about 60.3 million, driven by equity issuance and compensation. Management highlights bel-sar’s potential as a first-in-class, organ-preserving therapy across early choroidal melanoma, bladder cancer and other solid tumor indications, supported by favorable early safety and efficacy signals and multiple regulatory designations.
Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.
Aura Biosciences officer Conor Kilroy reported equity awards that increase his holdings. On March 2, 2026, he was granted a stock option for 112,661 shares of common stock at $0.00 per share and an award of 62,339 shares of common stock. The RSU shares vest in four equal annual installments starting January 15, 2027, while the option vests 25% on February 1, 2027 and the remainder in 36 monthly installments, all subject to continued service. After these grants, he directly owns 229,573 common shares and holds options for 112,661 shares.
Gibney Anthony S reported acquisition or exercise transactions in this Form 4 filing.
Aura Biosciences, Inc. reported that company officer Anthony S. Gibney received new equity awards. On March 2, 2026, he was granted 71,245 shares of common stock through a restricted stock unit award and a stock option for 128,755 shares.
The restricted stock units vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on his continued service. The stock option vests with 25% of the shares on February 1, 2027, and the remaining shares vest pro rata in 36 monthly installments, also subject to continued service.
Aura Biosciences reported new equity awards to director and officer Elisabet de los Pinos. On March 2, 2026, she acquired 166,000 shares of Common Stock through a restricted stock unit award at a grant price of $0.0000 per share, increasing her directly held Common Stock to 575,815 shares.
She also received a stock option for 249,000 shares of Common Stock at an exercise price of $0.0000 per share, with 249,000 option shares outstanding after the award. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, and the option vests 25% on February 1, 2027, with the remainder vesting pro rata in 36 monthly installments, in each case subject to her continued service.
Separately, 127,763 Common shares are held indirectly by the Elisabet de los Pinos Revocable Trust dated April 8, 2016, of which she is a trustee.
Aura Biosciences Chief Technology Officer Mark Plavsic reported equity grants. He acquired a stock option covering 112,661 shares and 62,339 shares of common stock through a restricted stock unit award.
The RSUs vest in four equal annual installments beginning on January 15, 2027. The option vests 25% on February 1, 2027, with the remaining shares vesting pro rata in 36 monthly installments, in each case contingent on his continued service.
Aura Biosciences reported that Chief Medical Officer Janet Jill Hopkins received new equity awards. She was granted a stock option for 160,944 shares of common stock at an exercise price of $0.00 per share, classified as a grant or award acquisition.
She also acquired 89,056 shares of common stock at $0.00 per share through a restricted stock unit award, bringing her directly held common stock to 321,340 shares after the transaction. The RSUs vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service.
The option vests with 25% of the underlying shares vesting on February 1, 2027, and the remaining 75% vesting pro rata in 36 monthly installments, also subject to her continued service on each vesting date.
Aura Biosciences, Inc. reported that Senior Vice President, Finance, Amy Elazzouzi received new equity awards. She was granted stock options for 80,472 shares at an exercise price of $0.00 and 44,528 shares of common stock via restricted stock units, both as compensation awards.
The restricted stock units vest in four substantially equal annual installments beginning on January 15, 2027, conditioned on continued service. The stock options vest with 25% on February 1, 2027, and the remaining 75% in 36 monthly installments, also subject to continued service.
Aura Biosciences reports amended Schedule 13G/A showing Advent-affiliated entities may beneficially own an aggregate 3.258% of common stock, equal to 2,023,857 shares as of December 31, 2025.
Dr. Rajesh Parekh, a general partner of Advent, is reported with options to purchase 48,000 shares and may be deemed to beneficially own 2,071,857 shares (3.335%) as of December 31, 2025. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
Aura Biosciences reports a proposed sale of 22,619 shares of common stock. The shares are issuable under a Restricted Stock Unit award granted pursuant to the Issuer's 2021 Stock Option and Incentive Plan on 02/03/2025 and are subject to vesting requirements.